Novo Nordisk AS (NVO.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Dec31

Ethic Inc. reduces its stake in Novo Nordisk

09:18

Novo Nordisk introduces GLP-1 class drugs into the nephrology field as part of its strategic focus on chronic kidney disease

07:30

Novo Nordisk's long-acting growth hormone Sogroya® approved for market in China

03:21

Dec30

Seeking Alpha publishes analysis suggesting oral Wegovy will pressure margins, recommends "Sell" for Novo Nordisk stock.

14:33

Analysis indicates Novo Nordisk's GLP-1 weight-loss drugs may offer additional health benefits.

13:40

Novo Nordisk and Eli Lilly lower prices of their weight-loss drugs in China

13:01

Schedules & Filings

Schedules

Filings

Feb4

Earning Release(EST)

FY2025 Annual Earning Release

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 11.78 B, Net Income 3.143 B, EPS 0.707

Novo Nordisk A/S (NVO.US) Q3 2025 Earnings Conference Call

Aug26

Distribution Plan(EST)

Cash dividend 0.5843 USD

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change